Method for evaluation of guidance equipments for agricultural vehicles and GNSS signals effect

Pesquisas indicam que o uso de novas técnicas no campo da mecanização agrícola, como o tráfego controlado por meio de direcionamento com auxílio de Sistemas de Navegação Global por Satélites (GNSS), pode diminuir as exigências por energia associadas às operações de campo e aumentar a produtividade da mão de obra e da cultura. Alguns autores já utilizaram diferentes metodologias para avaliar erros de paralelismo em sistemas de orientação de veículos, porém não há um procedimento-padrão para medi-los. Sendo assim, o objetivo deste trabalho foi implementar uma planilha eletrônica específica, determinar e comparar a acurácia no paralelismo de dois sistemas distintos de orientação de veículos (uma barra de luz e um piloto automático com atuador de volante) em trajetórias retilíneas e utilizando sinal de GPS com dois sistemas de correção diferencial (um com algoritmo interno e outro, um sinal via satélite com acurácia submétrica). Para a avaliação dos sistemas de correção, utilizou-se como referência o sinal de correção diferencial RTK (Real Time Kinematic) para realização de cinco passadas paralelas sucessivas para cada sistema de correção, caracterizando cinco repetições de cada tratamento. A planilha viabilizou o método de avaliação utilizado e os erros apresentados para as correções nos dois equipamentos analisados mostraram-se compatíveis com operações que exijam acurácia de paralelismo da ordem de decímetros.Researches indicate that the use of new techniques in agricultural machinery, as controlled traffic by steering systems with the use of Global Navigation Satellite Systems (GNSS) may decrease the energy demand associated to field operations and increase labor efficiency and crop yield. Some authors already use different methodologies to evaluate the parallelism errors in guidance systems for vehicles, but there is no standard methodology to measure them. So, the objective of these work was to develop a specific spreadsheet, determinate and compare the accuracy in the parallelism of two distinct guidance systems (a light bar and an universal autopilot) working at straight path using GPS signal with two differential correction systems (one with internal algorithm and the other with satellite signal and sub metric accuracy). To evaluate both systems a RTK (Real Time Kinematic) differential correction was used, realizing five parallel and successive paths for each system, characterizing five replications for each treatment. The spreadsheet enabled the evaluation method used, and the errors for both equipments and signals analyzed, showed to be compatible with field operations that demand parallelism accuracy in the order of decimeters.FAPES

Giant ovarian immature teratoma with bilateral mature teratoma: case report

Immature teratoma of the ovary is a malignant neoplasm composed of undifferentiated tissue that arises from embryonic cells. And the mature teratoma is a benign neoplasm composed of differentiated tissues. This paper aims to report the case of a 21-year-old pacient with giant immature teratoma in left ovary associated with mature ovarian teratoma bilateral, due to the association of teratoma with mature teratoma ipsilateral and contralaterally, combined with its outstanding increased size (36 cm), is unusual. Exploratory laparotomy, with cytoreductive pan-hysterectomy and bilateral salpingooferectomia were performed. The patient received adjuvant chemotherapy with BEP regimen (bleomycin, etoposide and cisplatin) in four cycles with intervals of 21 days, coursing with good evolutionO teratoma imaturo de ovário é uma neoplasia maligna que tem origem em células embrionárias composta de tecidos indiferenciados. E o teratoma maduro é uma neoplasia benigna formada por tecidos diferenciados. Este trabalho tem por objetivo relatar o caso de uma paciente de 21 anos de idade com teratoma imaturo gigante em ovário esquerdo associado a teratoma ovariano maduro bilateral, devido à associação do teratoma com teratoma maduro ipsi e contralateralmente, combinada ao marcante tamanho aumentado (36 cm) ser pouco comum. Foi realizada laparotomia exploratória, citorredutora, com pan-histerectomia e salpingooferectomia bilateral. A paciente recebeu quimioterapia adjuvante, com esquema BEP (bleomicina, etoposídeo e cisplatina) em quatro ciclos com intervalos de 21 dias, cursando com boa evoluçã

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.

Purpose T-cell-replete HLA-haploidentical donor hematopoietic transplantation using post-transplant cyclophosphamide was originally described using bone marrow (BM). With increasing use of mobilized peripheral blood (PB), we compared transplant outcomes after PB and BM transplants. Patients and Methods A total of 681 patients with hematologic malignancy who underwent transplantation in the United States between 2009 and 2014 received BM (n = 481) or PB (n = 190) grafts. Cox regression models were built to examine differences in transplant outcomes by graft type, adjusting for patient, disease, and transplant characteristics. Results Hematopoietic recovery was similar after transplantation of BM and PB (28-day neutrophil recovery, 88% v 93%, P = .07; 100-day platelet recovery, 88% v 85%, P = .33). Risks of grade 2 to 4 acute (hazard ratio [HR], 0.45; P \u3c .001) and chronic (HR, 0.35; P \u3c .001) graft-versus-host disease were lower with transplantation of BM compared with PB. There were no significant differences in overall survival by graft type (HR, 0.99; P = .98), with rates of 54% and 57% at 2 years after transplantation of BM and PB, respectively. There were no differences in nonrelapse mortality risks (HR, 0.92; P = .74) but relapse risks were higher after transplantation of BM (HR, 1.49; P = .009). Additional exploration confirmed that the higher relapse risks after transplantation of BM were limited to patients with leukemia (HR, 1.73; P = .002) and not lymphoma (HR, 0.87; P = .64). Conclusion PB and BM grafts are suitable for haploidentical transplantation with the post-transplant cyclophosphamide approach but with differing patterns of treatment failure. Although, to our knowledge, this is the most comprehensive comparison, these findings must be validated in a randomized prospective comparison with adequate follow-up

Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Acute graft-versus-host disease (aGVHD) is one of the major causes of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recently, aGVHD onset was linked to intestinal microbiota (IM) dysbiosis. However, other bacterial-rich gastrointestinal sites, such as the mouth, which hosts several distinctive microbiotas, may also impact the risk of GVHD. The dental biofilm microbiota (DBM) is highly diverse and, like the IM, interacts with host cells and modulates immune homeostasis. We characterized changes in the DBM of patients during allo-HSCT and evaluated whether the DBM could be associated with the risk of aGVHD. DBM dysbiosis during allo-HSCT was marked by a gradual loss of bacterial diversity and changes in DBM genera composition, with commensal genera reductions and potentially pathogenic bacteria overgrowths. High Streptococcus and high Corynebacterium relative abundance at preconditioning were associated with a higher risk of aGVHD (67% vs. 33%; HR = 2.89, P = 0.04 and 73% vs. 37%; HR = 2.74, P = 0.04, respectively), while high Veillonella relative abundance was associated with a lower risk of aGVHD (27% vs. 73%; HR = 0.24, P < 0.01). Enterococcus faecalis bloom during allo-HSCT was observed in 17% of allo-HSCT recipients and was associated with a higher risk of aGVHD (100% vs. 40%; HR = 4.07, P < 0.001) and severe aGVHD (60% vs. 12%; HR = 6.82, P = 0.01). To the best of our knowledge, this is the first study demonstrating that DBM dysbiosis is associated with the aGVHD risk after allo-HSCT

Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies

Leukodystrophies (LD) are devastating inherited disorders leading to rapid neurological deterioration and premature death. Hematopoietic stem cell transplantation (HSCT) can halt disease progression for selected LD. Cord blood is a common donor source for transplantation of these patients because it is rapidly available and can be used without full HLA matching. However, precise recommendations allowing care providers to identify patients who benefit from HSCT are lacking. In this study, we define risk factors and describe the early and late outcomes of 169 patients with globoid cell leukodystrophy, X-linked adrenoleukodystrophy, and metachromatic leukodystrophy undergoing cord blood transplantation (CBT) at an European Society for Blood and Marrow Transplantation center or at Duke University Medical Center from 1996 to 2013. Factors associated with higher overall survival (OS) included presymptomatic status (77% vs 49%; P = .006), well-matched (80 preCBT, 50% remained stable, 20% declined to 60 to 80, and 30% to, 60. Overall, an encouraging OS was found for LD patients after CBT, especially for those who are presymptomatic before CBT and received adequately dosed grafts. Early identification and fast referral to a specialized center may lead to earlier treatment and, subsequently, to improved outcomes

Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

Non peer reviewe

A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome

Wiskott-Aldrich syndrome is a severe X-linked recessive immune deficiency disorder. A scoring system of Wiskott-Aldrich syndrome severity (0.5-5) distinguishes 2 phenotypes: X-linked thrombocytopenia and classic Wiskott-Aldrich syndrome. Hematopoietic cell transplantation is curative for Wiskott-Aldrich syndrome, however the use of unrelated umbilical cord blood transplantation has seldom been described. We analyzed umbilical cord blood transplantation outcomes for 90 patients. Median age at umbilical cord blood transplantation was 1.5 years. Patients were classified according to clinical scores (2 (23%), 3 (30%), 4 (23%) and 5 (19%)). Most patients received HLA mismatched umbilical cord blood transplantation and myeloablative conditioning with anti-thymocyte globulin. Cumulative incidence of neutrophil recovery at day-60 was 89% and day-100 acute graft-versus-host disease grade II-IV was 38%; use of methotrexate for graft-versus- host disease prophylaxis delayed engraftment (p=0.02), but decreased acute graft-versus-host disease (p=0.03). At 5-year, overall survival and event-free survival were 75% and 70%, respectively. Estimated 5 year- event-free survival was 83%, 73% and 55% for patients with clinical score 2, 4-5 and 3, respectively. In multivariate analysis, age<2years at umbilical cord blood transplantation and clinical phenotype X-linked thrombocytopenia were associated with improved event-free survival. Overall survival tended to be improved after 2007 (p=0.09). In conclusion, umbilical cord blood transplantation is a good alternative option for young children with Wiskott-Aldrich syndrome lacking an HLA identical stem cell donor